New cancer drug enters first human safety testing
NCT ID NCT06082960
Summary
This is the first human study of an experimental cancer drug called GS-9911. Researchers are testing its safety and finding the right dose when given alone or combined with an immunotherapy drug. The study includes 45 adults with advanced solid tumors who have run out of standard treatment options.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
NEXT Oncology
San Antonio, Texas, 78229, United States
-
Peter MacCallum Cancer Centre
Melbourne, Victoria, 3000, Australia
-
SCRI Oncology Partners
Nashville, Tennessee, 37203, United States
-
Smilow Cancer Hospital Phase 1 Unit
New Haven, Connecticut, 06520, United States
-
South Texas Accelerated Research Therapeutics, LLC
San Antonio, Texas, 78229, United States
-
University Health Network, Princess Margaret Cancer Centre
Toronto, M5G, Canada
Conditions
Explore the condition pages connected to this study.